Income Statement
TELOMIR PHARMACEUTICALS, INC.
TELO
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Revenue
|
- | - | - |
|
Cost of Revenue
|
- | - | - |
|
Gross Profit
|
- | - | - |
|
Operating Expenses
|
10.54 | 12.24 | 3.94 |
|
Research & Development
|
2.44 | 2.24 | 1.57 |
|
Selling, General & Administrative
|
8.10 | 9.64 | 0.60 |
|
Other Operating Expenses
|
- | - | - |
|
Operating Income
|
-10.54 | -12.24 | -3.94 |
|
Non-Operating Income
|
- | - | - |
|
Interest Income
|
0.13 | 0.05 | - |
|
Interest Expense
|
- | - | 1.64 |
|
Other Non-Op Income / Expense
|
- | - | - |
|
Income Before Tax
|
- | - | - |
|
Income Tax Expense
|
- | - | - |
|
Non-Controlling Interest
|
- | - | - |
|
Net Income
|
-10.41 | -16.53 | -13.07 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY |
|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - |
|
EBITDA
|
-10.54 | -12.24 | -3.94 |
|
Earnings Per Share (Basic)
|
-0.33 | 0.56 | -0.48 |
|
Diluted EPS
|
-0.33 | 0.56 | -0.45 |
|
Weighted Average Shares
|
31.65 | 29.54 | 27.30 |
|
Diluted Weighted Avg Shares
|
31.65 | 29.54 | 29.02 |
|
Comprehensive Income
|
- | - | - |